Samar Nasser Chehimi

Dr. Samar Nasser Chehimi

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2023 in Genes
Verified
Journal Article
Open access
PDF file
SCSamar Nasser Chehimi
Samar Nasser Chehimi
RCRichard C. Crist
Richard C. Crist
BRBenjamin C. Reiner
Benjamin C. Reiner
The development of single-cell and single-nucleus transcriptome technologies is enabling the unraveling of the molecular and cellular heterogeneity of psychiatric disorders. The complexity of the brain and the relationships between different brain regions can be better understood through the classification of individual cell populations based on their molecular markers and transcriptomic features. Analysis of these unique cell types can explain their involvement in the pathology of psychiatric disorders. Recent studies in both human and animal models have emphasized the importance of transcriptome analysis of neuronal cells in psychiatric disorders but also revealed critical roles for non-neuronal cells, such as oligodendrocytes and microglia. In this review, we update current findings on the brain transcriptome and explore molecular studies addressing transcriptomic alterations identified in human and animal models in depression and stress, neurodegenerative disorders (Parkinson’s and Alzheimer’s disease), schizophrenia, opioid use disorder, and alcohol and psychostimulant abuse. We also comment on potential future directions in single-cell and single-nucleus studies.

11 June 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
LDLéa Décarie-Spain
Léa Décarie-Spain
CGCindy Gu
Cindy Gu
LLLogan Tierno Lauer
Logan Tierno Lauer
KSKeshav S. Subramanian
Keshav S. Subramanian
SCSamar Nasser Chehimi
Samar Nasser Chehimi
SKScott Kanoski
Scott Kanoski
The ability to encode and retrieve meal-related information is critical to efficiently guide energy acquisition and consumption, yet the underlying neural processes remain elusive. Here we reveal that ventral hippocampus (HPCv) neuronal activity dynamically elevates between eating bouts during meal consumption and this response is predictive of performance in a foraging-related memory test for the spatial location of a previously consumed meal. Targeted recombination-mediated ablation of HPCv meal-responsive neurons impairs meal location memory without influencing food motivation or spatial memory for escape location. These HPCv meal-responsive neurons project to the lateral hypothalamic area (LHA) and are enriched in serotonin 2a receptors (5HT2aR). Either chemogenetic silencing of HPCv-to-LHA projections or intra-HPCv 5HT2aR antagonist yielded meal location memory deficits, as well as increased caloric intake driven by shorter temporal intervals between meals. Collective results identify a population of HPCv neurons in male rats that dynamically respond during eating to encode meal-related memories.

1 August 2020 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
ÉZÉvelin A. Zanardo
Évelin A. Zanardo
FMFabíola P. Monteiro
Fabíola P. Monteiro
SCSamar Nasser Chehimi
Samar Nasser Chehimi
YOYanca G. Oliveira
Yanca G. Oliveira
ADAlexandre T. Dias
Alexandre T. Dias
LKLeslie Kulikowski
Leslie Kulikowski

7 January 2026 in Nature
Verified
Journal Article
Open access
PDF file
COCorinna S. Oswell
Corinna S. Oswell
SRSophie A. Rogers
Sophie A. Rogers
JJJustin G. James
Justin G. James
NMNora M. McCall
Nora M. McCall
AHAlex I. Hsu
Alex I. Hsu
GCGregory Corder
Gregory Corder
The anterior cingulate cortex is a key brain region involved in the affective and motivational dimensions of pain, but how opioid analgesics modulate this cortical circuit remains unclear1. Uncovering how opioids alter nociceptive neural dynamics to produce pain relief is essential for developing safer and more targeted treatments for chronic pain. Here we show that a population of cingulate neurons encodes spontaneous pain-related behaviours and is selectively modulated by morphine. Using deep learning behavioural analyses combined with longitudinal neural recordings in mice, we identified a persistent shift in cortical activity patterns following nerve injury that reflects the emergence of an unpleasant, affective chronic pain state. Morphine reversed these neuropathic neural dynamics and reduced affective–motivational behaviours without altering sensory detection or reflexive responses, mirroring how opioids alleviate pain unpleasantness in humans. Leveraging these findings, we built a biologically inspired chemogenetic gene therapy that targets opioid-sensitive neurons in the cingulate using a synthetic μ-opioid receptor promoter to drive inhibition2. This opioid-mimetic chemogenetic gene therapy recapitulated the analgesic effects of morphine during chronic neuropathic pain, thereby offering a new strategy for precision pain management that targets a key nociceptive cortical opioid circuit with safe, on-demand analgesia.

25 July 2025 in Science Advances
Verified
Journal Article
Open access
JWJessica A. Wojick
Jessica A. Wojick
APAlekh Paranjapye
Alekh Paranjapye
JCJuliann K. Chiu
Juliann K. Chiu
COCorinna S. Oswell
Corinna S. Oswell
MMMalaika Mahmood
Malaika Mahmood
GCGregory Corder
Gregory Corder
The basolateral amygdala (BLA) assigns valence to sensory stimuli, with a dedicated nociceptive ensemble encoding the negative valence of pain. However, the effects of chronic pain on the transcriptomic signatures and projection architecture of this BLA nociceptive ensemble are not well understood. Here, we show that optogenetic inhibition of the nociceptive BLA ensemble reduces affective-motivational behaviors in chronic neuropathic pain. Single-nucleus RNA sequencing revealed peripheral injury–induced changes in genetic pathways involved in axonal and presynaptic organization in nociceptive BLA neurons. Next, we identified a previously uncharacterized nociceptive hotspot in the nucleus accumbens shell that is innervated by BLA nociceptive neurons. Axonal calcium imaging of BLA projections to the accumbens and chemogenetic inhibition of this pathway revealed pain-related transmission from the amygdala to the medial nucleus accumbens, facilitating both acute and chronic pain affective-motivational behaviors. Together, this work defines a critical nociceptive amygdala-striatal circuit underlying pain unpleasantness across pain states.

30 September 2019 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
SCSamar Nasser Chehimi
Samar Nasser Chehimi
ÉZÉvelin A. Zanardo
Évelin A. Zanardo
JCJosé R. M. Ceroni
José R. M. Ceroni
ANAmom M. Nascimento
Amom M. Nascimento
FMFabrícia A. R. Madia
Fabrícia A. R. Madia
LKLeslie Kulikowski
Leslie Kulikowski
Background: Cri du chat syndrome (CdCS) is a rare syndrome caused by a partial or complete deletion of the short arm of chromosome 5 (5p‐). The main clinical features include a high‐pitched cry, facial asymmetry, microcephaly, round face at birth, epicanthal folds, hypotonia, delayed growth and development.Methods: We studied 14 Brazilian patients with CdCS using genomic array in order to better define the 5p breakpoints and recognize copy number variations (CNVs) that contribute to clinical manifestations associated with the syndrome.Results: Array confirmed terminal deletions in 13 patients and an interstitial deletion in one patient. It was also possible to map the breakpoints and associate a genomic region of 4.7 Mb to the development of head circumference and cat‐like cry. We also found other CNVs concomitant to the 5p deletion including a 9p duplication, a 17q deletion, and a 22q deletion in three different patients.Conclusion: With advancements of molecular cytogenomic methods in the last two decades, it was possible to evidence cryptic alterations and improve the genotype–phenotype correlation. In this work, we describe a new genomic region associated with microcephaly and cat‐like cry and highlight the importance of precise delineation of 5p deletion breakpoints and detection of other CNVs in CdCS patients to improve genotype–phenotype correlation to perform a complete clinical and molecular diagnosis.